Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Hanx Biopharmaceuticals (Wuhan) Co's Net Debt Paydown Yield % was 0%.
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hanx Biopharmaceuticals (Wuhan) Co Net Debt Paydown Yield % Chart
Hanx Biopharmaceuticals (Wuhan) Co Annual Data
Trend
Dec23
Dec24
Dec25
Net Debt Paydown Yield %
0.00
0.00
-2.26
Hanx Biopharmaceuticals (Wuhan) Co Semi-Annual Data
Dec23
Dec24
Dec25
Jun26
Net Debt Paydown Yield %
0.00
0.00
-2.26
0.00
HKSE:03378 vs VRTX, REGN, MRNA: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, Hanx Biopharmaceuticals (Wuhan) Co's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hanx Biopharmaceuticals (Wuhan) Co Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hanx Biopharmaceuticals (Wuhan) Co's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Hanx Biopharmaceuticals (Wuhan) Co's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) has a Net Debt Paydown Yield % of 0% as of Sep. 13, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Hanx Biopharmaceuticals (Wuhan) Co and its competitors. According to the industry distribution chart, Hanx Biopharmaceuticals (Wuhan) Co ranks #999999 out of 1146 companies in the Biotechnology industry.
Is Hanx Biopharmaceuticals (Wuhan) Co's Net Debt Paydown Yield % too high?
Hanx Biopharmaceuticals (Wuhan) Co's current Net Debt Paydown Yield % is 0%. Based on the distribution chart, Hanx Biopharmaceuticals (Wuhan) Co ranks #999999 out of 1146 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hanx Biopharmaceuticals (Wuhan) Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hanx Biopharmaceuticals (Wuhan) Co's Net Debt Paydown Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hanx Biopharmaceuticals (Wuhan) Co ranks #999999 out of 1146 companies for Net Debt Paydown Yield %. This places Hanx Biopharmaceuticals (Wuhan) Co in the lower half of its industry. The industry median Net Debt Paydown Yield % is 0.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,146 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Hanx Biopharmaceuticals (Wuhan) Co and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hanx Biopharmaceuticals (Wuhan) Co's current Net Debt Paydown Yield % is 0%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hanx Biopharmaceuticals (Wuhan) Co stock overvalued right now?
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) has a current Net Debt Paydown Yield % of 0%. The current Net Debt Paydown Yield % is 0%. Hanx Biopharmaceuticals (Wuhan) Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378), the current Net Debt Paydown Yield % is 0% as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hanx Biopharmaceuticals (Wuhan) Co Ltd is a biotech company with in-house capabilities in structural biology, translational medicine, and clinical development, focused on developing immunotherapeutic products. Its product pipeline comprises one Core Product and nine other pipeline candidates: three clinical-stage drug candidates focused on oncology, including its Core Product HX009 and Key Products HX301 and HX044; and seven preclinical-stage drug candidates, including an antibody drug conjugate, a bispecific antibody, and a monoclonal antibody for both autoimmune and oncology markets.
11GF Score
Get the complete analysis for HKSE:03378
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03378 has been successfully added to your 
